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REVIEW RETURNED
24-Oct-2018
GENERAL COMMENTS
Sample size calculation is not convenient. I suppose that this calculation is based on a 2 sample t test. With 26 patients in each group authors may get a statistical test result when comparing the mean values of the primary outcome (time between induction and delivery). However the mean difference may be rather small and not clinically relevant. In my opinion it would be better to set the null difference at 2 hours (for instance). As 40 patients per group will be included this should not be problematical. 
VERSION 1 -AUTHOR RESPONSE
Comments of the first reviewer # Please state any competing interests or state 'None declared': None declared « Competing interest: None declared. » was added page 11 of the revised manuscript. # The study has made a power calculation for determining a difference of 9 hours. This is not stated in the abstract, which it should.
The power calculation was made to determine a difference of 10 hours. This element was added in the abstract : « To sufficiently demonstrate a difference (10 hours) between groups-with a statistical power of 90% and a two-tailed α of 5%-40 patients per group will be required. » # In the power calculation is stated 26 per group is needed however they aim to include 40 per group due to statistical power for secondary outcomes. However, the power calculation for secondary outcomes is not written.
As the power calculation for secondary outcomes could not be calculated accurately for all the criteria, the authors choose to include 40 patients per group to observe a higher mean difference, expected to be more clinically relevant. A sample size of 40 patients per group will allow to show an effect size of 0,7, which seems clinically relevant according to the definition of Cohen whatever the criterion considered (Cohen J.,1988 ; Statistical power analysis for the behavioral sciences. Lawrence Erlbaum associates, publishers). # The issue of risk of infection should be discussed in detail in the introduction. It is well known that the number of vaginal examinations is associated with risk of chorioamniotis (Seaward AJOG 1997) . It is well known that insertion of catheters create increased risk of infection potentially through a biofilm (Curtis Nickel J Can J Infec Dis 1992). With the results from the Mackeen study the risk of infection should be carefully explored. Is the study ethical to conduct?
The authors agree that it is important to carefully explored the risk of infection. To ensure patient safety, sequential analysis will be performed every 20 inclusions to control the rate of complications (cesarean or infections). Maternal and foetal infections are assessed on the basis of clinical (fever, postpartum endometritis), bacteriological and histological criteria. The study of Mackeen was the only study which demonstrated the highest risk of chorioamnionitis in case of mechanical ripening of PROM at term. Other studies comparing mechanical ripening with prostaglandin didn't find this risk. Studies even found less hospitalization in pediatrics and suspected maternal infection in case of mechanical ripening than prostaglandin (p <0.01 and p = 0.03, respectively), but in a context without PROM (PROOBAT study). Also, in the study of Mackeen, some patients had a positive GBS portage which is know to be a risk factor of chorioamnionitis. In our study, positive GBS portage is an exclusion criteria. In Mackeen study, antibiotics were given for positive GBS prophylaxis and suspect intraamniotic infection. In our study, antibioprophylaxis is systematically administered after 12 hours of PROM. With these two precautions, we hope to avoid higher risk of chorioamnionitis in the group with mechanical device. These informations were added in the introduction to clarify this point. The frequency of vaginal examinations is the same whatever the ripening device.
Comments of the second reviewer # Sample size calculation is not convenient. I suppose that this calculation is based on a 2 sample t test. With 26 patients in each group authors may get a statistical test result when comparing the mean values of the primary outcome (time between induction and delivery). However the mean difference may be rather small and not clinically relevant. In my opinion it would be better to set the null difference at 2 hours (for instance). As 40 patients per group will be included this should not be problematical.
The sample size was determined to highlight a clinical and relevant absolute difference of 10 hours (with a two-sided type I error of 5% and a statistical power of 90%). This hypothesis was based on previous studies which showed similar differences (around 9h-10h): US study published in 2014 comparing the induction of labour by Foley catheter versus vaginal prostaglandin found a significant decrease in time from onset of the induction to delivery (12hours in the Foley group versus 22hours in the prostaglandin group, p <0.01). Considering these bibliographical data, it seemed unlikely that the difference between groups will be less than 2 hours. The authors finally chose to include 40 patients per group which should allow to observe a clinically relevant difference and to ensure satisfactory statistical power for the main secondary objectives. # For what reason should the values of the primary outcome be treated as censored data? These values can be measured precisely. Cox regression analysis and logrank tests as well as the Kaplan Meier method do not require censored data.
Comparison of primary outcomes between randomized groups will be performed without censored data in the primary analysis method. In a secondary analysis, primary outcomes will be also treated as censored data associated with favorable outcome to consider uncomplicated pregnancy without cesarean section, as proposed by Amorosa MD. et al, 2017 (reference n°9). The authors apologize for not having explained this point in the manuscript. These elements were added in the paragraph 2.2.10 to clarify this point.
VERSION 2 -REVIEW

REVIEWER
Ellen Løkkegaard, Professor, Consultant, PhD Department of Obstetrics and Gynecology, North Zealand Hospital, Hillerød, University of Copenhagen, Dyrehavevej 29, 3400 Hillerød, Denmark REVIEW RETURNED 08-Feb-2019
GENERAL COMMENTS
The manuscript has improved thought I suggest the detailed discussion on the litterature on risk of infection in the response letter should be included in the introduction of the publication.
